IVA
Inventiva S.A.·Healthcare
5.22
1.163%(+0.06)
Close PriceLast Updated: — ET
52W L: $2.8552W H: $7.98
IVA NEWS
globenewswire.com
1d ago
Inventiva Reports 2026 First Quarter Financial Information¹
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first quarter of 2026, including its cash, cash equivalents and revenues.
globenewswire.com
6d ago
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain will present at at the upcoming 2026 Jefferies Global Healthcare Conference. The conference is being held June 2-4, 2026, in New York City.
seekingalpha.com
May 15
Inventiva's Speculative Upside Through MASH Is Promising
Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA's balance sheet has sufficient financing to reach that readout. But please bear in mind that it's a binary outcome.
globenewswire.com
May 13
Inventiva to Present Abstracts at the EASL Congress 2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona.
globenewswire.com
May 13
Inventiva to Present Abstracts at the EASL Congress 2026
Daix (France), New York City (New York, United States), May 13, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona.
globenewswire.com
May 13
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 - Inventiva (Euronext Paris et NASDAQ: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique spécialisée dans le développement de thérapies par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui la présentation de deux abstracts lors du prochain congrès annuel de l'European Association for the Study of the Liver, EASL Congress 2026, qui se tiendra du 27 au 30 mai 2026 à Barcelone.
